ArticleCancer science2012
Testin is a tumor suppressor and prognostic marker in breast cancer.
Article in Cancer science, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 41 citations in OpenAlex.
- The value of lung function assessment and Testin expression detection in clinicopathological features and prognosis of NSCLC patients.Journal of cardiothoracic surgery · 2024Article
- The Expression of Testin, Ki-67 and p16 in Cervical Cancer Diagnostics.Current issues in molecular biology · 2023Article
- Stress fiber strain recognition by the LIM protein testin is cryptic and mediated by RhoA.Molecular biology of the cell · 2021Article
- Silencing of Testin expression is a frequent event in spontaneous lymphomas from Trp53-mutant mice.Scientific reports · 2020Article
- Response gene to complement-32 promotes cell survival via the NF-κB pathway in non-small-cell lung cancer.Experimental and therapeutic medicine · 2020Article
- The Role of Testin in Human Cancers.Pathology oncology research : POR · 2019Review
- CFP suppresses breast cancer cell growth by TES-mediated upregulation of the transcription factor DDIT3.Oncogene · 2019Article
- TES functions as a Mena-dependent tumor suppressor in gastric cancer carcinogenesis and metastasis.Cancer communications (London, England) · 2019Article
- Testin protects against cardiac hypertrophy by targeting a calcineurin-dependent signalling pathway.Journal of cellular and molecular medicine · 2019Article
- The Different Facades of Retinal and Choroidal Endothelial Cells in Response to Hypoxia.International journal of molecular sciences · 2018Review
- Angiogenic and Immunologic Proteins Identified by Deep Proteomic Profiling of Human Retinal and Choroidal Vascular Endothelial Cells: Potential Targets for New Biologic Drugs.American journal of ophthalmology · 2018Article
- Expression of Tim-3 in breast cancer tissue promotes tumor progression.International journal of clinical and experimental pathology · 2018Article
- Article
- Germline large genomic alterations on 7q in patients with multiple primary cancers.Scientific reports · 2017Article
- The PET and LIM1-2 domains of testin contribute to intramolecular and homodimeric interactions.PloS one · 2017Article
- TESTIN Induces Rapid Death and Suppresses Proliferation in Childhood B Acute Lymphoblastic Leukaemia Cells.PloS one · 2016Article
- Testin on Atherosclerosis in Rabbits.Chinese medical journal · 2015Article
- Racial variation in breast tumor promoter methylation in the Carolina Breast Cancer Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2015Article
- Molecular characterization of common fragile sites as a strategy to discover cancer susceptibility genes.Cellular and molecular life sciences : CMLS · 2014Review
- TES was epigenetically silenced and suppressed the epithelial-mesenchymal transition in breast cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The testin (TES) gene was previously identified in the fragile chromosomal region FRA7G at 7q31.2. In the present study, we aimed to investigate the candidate tumor suppressor function of TES and explore its correlations to clinicopathologic features and prognosis in breast cancer. In clinical samples, we showed that the expression of TES decreased gradually from normal through ductal hyperplasia without atypia, atypical ductal hyperplasia, and ductal carcinoma in situ, to invasive ductal carcinoma. To explore the possible tumor suppressing function of TES, the expression of TES in breast cancer cells was manipulated by ectopic expression or by RNAi. We revealed that ectopic TES expression significantly inhibited cell proliferation, invasive ability, and angiogenesis, whereas knockdown of TES by RNAi enhanced cell proliferation, invasive ability, and angiogenesis. In an animal model, TES markedly inhibited breast cancer cell xenograft formation in athymic nude mice and reduced breast cancer cell metastasis to lung. Moreover, we revealed that TES inhibited the invasion and angiogenesis of breast cancer partially through miR-29b-mediated MMP-2 inhibition. Using the tissue microarray of breast cancer from Yale University, we found that lower TES expression was an independent prognostic factor for shorter overall survival and disease-free survival with univariate and multivariate analyses. Taken together, these data suggest that TES, as a valuable marker of breast cancer prognosis, plays an important role in the development and progression of breast cancer. TES may be an effective novel target in breast cancer prevention and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.